Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen

Phase 4 Completed 20 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess if a combination of everolimus, steroids, and mycophenolate mofetil is associated with a better renal function than sirolimus.

Timeline

Start: 2005-02
Primary completion: 2006-03
Completion: —

Publications

Results Kamar N, Jaafar A, Esposito L, Ribes D, Durand D, Di-Giambattista F, Tack I, Rostaing L. Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot study. Clin Nephrol. 2008 Aug;70(2):118-25. doi: 10.5414/cnp70118.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	8 mg	—

Indications

No indication recorded.